Company news

Hansa Biopharma AB news in 2025

Hansa Biopharma AB's news releases, calls and decks from 2025, newest first.

View company

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

December 19, 2025

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results

October 30, 2025

Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

October 29, 2025

Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV

October 10, 2025

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

September 24, 2025

Hansa Biopharma announces key executive appointments to support continued growth

July 29, 2025

Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results

July 17, 2025

Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer

July 8, 2025

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

June 30, 2025

Hansa Biopharma to attend BIO International Convention

June 11, 2025

Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025

June 9, 2025

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

May 14, 2025

Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.

May 13, 2025

Calls in 2025

Decks in 2025